HAMPTON, N.J., Feb. 13, 2017 -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today upcoming investor events for February and March.
Upcoming Investor Conferences
Anthony Marucci, Co-founder, President and Chief Executive Officer, and Thomas Davis, M.D., Executive Vice President and Chief Medical Officer, will participate in presentations at the following conferences:
- Leerink Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017 at 9:30 a.m. EST in New York – fireside chat
- Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 9:20 a.m. EST in Boston – corporate presentation
Live webcasts of the presentations will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay of the presentations will be available for seven days following each event.
2016 Year-End Results and Conference Call/Webcast
- Celldex will release fourth quarter and year-end 2016 financial results on Tuesday, March 14, 2017 after the U.S. financial markets close.
- Celldex will host a conference call/webcast at 4:30 p.m. EDT on the same day to provide an in-depth update on its pipeline and upcoming milestones for 2017.
Event details, including conference call phone numbers, can be accessed on the "Events & Presentations" page under the "Investors & Media" section of the Celldex website.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Contact Sarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 [email protected] Charles Liles Associate Director of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3107 [email protected]


Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S.
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 



